Clarus' Jatenzo Suffers From Off-Label Concerns At US Advisory Committee
Executive Summary
Oral testosterone candidate loses close vote as many panelists worry that convenience could spur misuse; REMS could offer reassurance.
You may also be interested in...
Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia
The latest drug development news and highlights from our US FDA Performance Tracker.
Spring Awakening: NDA Submissions To Watch For
If companies meet their publicly stated NDA filing targets, at least four breakthrough-designated therapies will arrive at US FDA in March.
Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic
The latest drug development news and highlights from our US FDA Performance Tracker.